References
- Adeniran A, Zhu Z, Gandhi M, et al (2006). Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol, 30, 216-22. https://doi.org/10.1097/01.pas.0000176432.73455.1b
- Agac A, Kutun S, cetin A (2013). Are the characteristics of thyroid cancer different in young patients? J Pediatr Endocrinol Metab, 27,497-502.
- Cooper D, Doherty G, Haugen B, et al (2009). Revised american thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid, 19, 1167-214.
- Davies L, Welch H (2014). Current Thyroid Cancer Trends in the United States. JAMA Otolaryngol Head Neck Surg, 140, 317-22. https://doi.org/10.1001/jamaoto.2014.1
- Danese D, Gardini A, Farsetti A, et al (1997). Thyroid carcinoma in children and adolescents. Eur J Pediatr, 156, 190-4. https://doi.org/10.1007/s004310050580
- Degroot L, Kaplan E, McCormick M, et al (1990). Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab, 71, 414-24. https://doi.org/10.1210/jcem-71-2-414
- Faggiano A, Coulot J, Bellon N, et al (2004). Age-dependent variation of follicular size and expression of iodine transporters in human thyroid tissue. J Nucl Med, 45, 232-7.
- Farahati J, Reiners C, Demidchik E (1999). Is the UICC/AJCC classification of primary tumor in childhood thyroid carcinoma valid? J Nucl Med, 40, 2125.
- Frankenthaler R, Sellin R, Cangir A, et al (1990). Lymph node metastasis from papillary-follicular thyroid carcinoma in young patients. Am J Surg, 160, 341-3. https://doi.org/10.1016/S0002-9610(05)80538-0
- Gulcelik M, Kuru B, Dincer H, et al (2012). Complications of completion versus total thyroidectomy. Asian Pac J Cancer Prev, 13, 5225-8. https://doi.org/10.7314/APJCP.2012.13.10.5225
- Handkiewicz-Junak D, Wloch J, Roskosz J, et al (2007). Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer. J Nucl Med, 48, 879-88. https://doi.org/10.2967/jnumed.106.035535
- Hovens G, Stokkel M, Kievit J, et al (2007). Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab, 92, 2610-5. https://doi.org/10.1210/jc.2006-2566
- Kim SS, Kim SJ, Kim IJ, et al (2012). Comparison of clinical outcomes in differentiated thyroid carcinoma between children and young adult patients. Clin Nucl Med, 37, 850-3. https://doi.org/10.1097/RLU.0b013e318262c5d6
- Lazar L, Lebenthal Y, Steinmetz A, et al (2009). Differentiated thyroid carcinoma in pediatric patients: comparison of presentation and course between pre-pubertal children and adolescents. J Pediatr, 154, 708-14. https://doi.org/10.1016/j.jpeds.2008.11.059
- Lima J, Trovisco V, Soares P, et al (2004). BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab, 89, 4267-71. https://doi.org/10.1210/jc.2003-032224
- Lupi C, Giannini R, Ugolini C, et al (2007). Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab, 92, 4085-90. https://doi.org/10.1210/jc.2007-1179
- Mehta V, Nikiforov Y, Ferris R (2013). Use of molecular biomarkers in FNA specimens to personalize treatment for thyroid surgery. Head Neck. 35, 1499-506.
- Miller R, L Young J, Novakovic B (1995). Childhood cancer. Cancer, 75, 395-405. https://doi.org/10.1002/1097-0142(19950101)75:1+<395::AID-CNCR2820751321>3.0.CO;2-W
- Patel A, Jhiang S, Dogra S, et al (2002). Differentiated thyroid carcinoma that express sodium-iodide symporter have a lower risk of recurrence for children and adolescents. Pediatr Res, 52, 737-44. https://doi.org/10.1203/00006450-200211000-00021
- Riesco G, Gutierrez P, Garcia M, et al (2006). The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr relat cancer, 13, 257-69. https://doi.org/10.1677/erc.1.01119
- Ringel M, Anderson J, Souza S, et al (2001). Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer. Mod Pathol, 14, 289-96. https://doi.org/10.1038/modpathol.3880305
- Yu WB, Tao SY, Zhang NS (2012). Is level V dissection necessary for low-risk patients with papillary thyroid cancer metastasis in lateral neck levels II, III, and IV. Asian Pac J Cancer Prev, 13, 4619-22. https://doi.org/10.7314/APJCP.2012.13.9.4619
- Zaman MU, Fatima N, Padhy AK, et al (2013).Controversies about radioactive iodine-131 remnant ablation in low risk thyroid cancers: are we near a consensus? Asian Pac J Cancer Prev, 14, 6209-13. https://doi.org/10.7314/APJCP.2013.14.11.6209
Cited by
- MiR-99a Inhibits Cell Proliferation and Tumorigenesis through Targeting mTOR in Human Anaplastic Thyroid Cancer vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.4937
- Comparison of differentiated thyroid cancer in children and adolescents (≤20 years) with young adults vol.84, pp.4, 2015, https://doi.org/10.1111/cen.12845
- Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer vol.14, pp.1, 2016, https://doi.org/10.1186/s12967-016-0958-x
- Single Point Mutations in Pediatric Differentiated Thyroid Cancer vol.27, pp.2, 2017, https://doi.org/10.1089/thy.2016.0339
- Initial Treatment Patterns in Younger Adult Patients with Differentiated Thyroid Cancer in California vol.25, pp.5, 2015, https://doi.org/10.1089/thy.2014.0610
- Promoter Mutations in Pediatric Thyroid Cancer vol.26, pp.2, 2016, https://doi.org/10.1089/thy.2015.0510